CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 149 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,412 | +94.2% | 38,150 | +44.3% | 0.01% | +42.9% |
Q3 2023 | $727 | -100.0% | 26,434 | -80.5% | 0.01% | -82.9% |
Q1 2021 | $2,792,000 | -6.6% | 135,552 | -20.5% | 0.04% | +41.4% |
Q4 2020 | $2,989,000 | +293.8% | 170,591 | +192.0% | 0.03% | +45.0% |
Q2 2020 | $759,000 | – | 58,415 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |